RiboNova Biopharma Secures Over RMB 200 Million in Series E Financing to Accelerate Global siRNA Therapeutics Strategy
Panlin Capital
Technology Innovation-Oriented Early-Stage and Mid-Stage Venture Capital Institutions
Ribo Life Science
Small Nucleic Acid Drug Developer
Mingxin Capital
--
Suzhou Ribo Life Science Co., Ltd. ("Ribo Life Science" or "the Company") announced that it has recently completed a new round of private equity financing exceeding 200 million RMB. This round of financing was led by Mingxin Capital, with participation from Kunshan High-Tech Venture Capital, Kunshan Guoke Venture Capital Co., Ltd., Chouqin Venture Capital, Panlin Capital, Beijing Lang Ma Feng VC LTD., and Shenzhen Xinchuang Medical Private Equity Investment Fund Partnership (Limited Partnership). The proceeds from this financing will mainly be used to accelerate the advancement of the company's self-developed clinical pipelines in therapeutic areas such as cardiovascular, metabolic, renal, and liver diseases, further innovate and develop the extrahepatic delivery technology platform, and strengthen global R&D and industrial capability building.
Since its establishment, with the high recognition and firm support of many well-known investors, the company has cumulatively completed multiple rounds of financing exceeding 1.8 billion RMB. From being one of the earliest pioneers in China's small nucleic acid field to becoming a global leader in siRNA therapy, Ribo Life Science has witnessed the vigorous development of small nucleic acid drug research and has accompanied and led the growth of China’s siRNA industry. Currently, with a highly forward-looking global strategic layout, the company has built multiple research and development centers in Kunshan (Suzhou), Beijing, and Europe, as well as a globally integrated small nucleic acid drug development system. Through independent innovation, it has developed a rich pipeline of siRNA drugs and achieved full lifecycle technology coverage for small nucleic acid drugs from early-stage research to commercialization.
Dr. Liang Zicai
Chairman and CEO of Ribo Life Science
With the strong support and high trust from all investors, Ribo Life Science has always adhered to the original aspiration of ‘becoming a global leading nucleic acid pharmaceutical enterprise’, achieving comprehensive leapfrog development from breakthroughs in bottleneck technologies to the layout of clinical pipelines. The company will continue to advance its R&D strategy with a global perspective, consolidating its global competitiveness in the small nucleic acid field through the dual drivers of international product development and an independent innovation platform. This will further create continuous value for shareholders and bring breakthrough treatment solutions to patients.
Dr. Xu Lixin
Founding Partner of Mingxin Capital
As one of the most disruptive directions in the current biopharmaceutical field, siRNA has significant advantages over traditional drug forms in terms of dosing cycles, patient compliance, R&D cycles, cost, and success rates, making it a key focus of our fund's investment strategy. Ribo Life Science, as a leading company in this field, has multiple clinical-stage pipelines that are globally recognized for their leadership. Its international team demonstrates global vision and industry-leading expertise. We are honored to lead this round of financing for Ribo Life Science through Jinan Mingxin Industrial Investment Fund. Moving forward, we will firmly support and continue to assist the company in expanding international cooperation, benefiting patients worldwide.
About Ribo Life Science
Ribo Life Science is a global leader specializing in the research and development of small nucleic acid (siRNA) drugs. Ribo Life Science aligns with the innovative frontier of international small nucleic acid technology, committing to the iterative R&D of small nucleic acid chemical modification and drug delivery technologies. It has established an independent and controllable, fully integrated small nucleic acid drug R&D platform that supports all stages of research for small nucleic acid drugs from early development to industrialization. The company has built a rich product pipeline covering cardiovascular, metabolic, liver, kidney, and other therapeutic areas, including its self-developed liver-targeting RiboGalSTAR.TMDelivery technology has advanced multiple products to Phase II clinical trials, with efficacy and safety well-validated in clinical studies. The company adheres to a differentiated approach in target and product development, supported by an international innovative R&D team. It conducts research, development, and commercialization globally, striving to bring new therapeutic options to patients as soon as possible. Headquartered in Kunshan, Jiangsu, the company has R&D centers in Beijing and Mölndal, Sweden. For more information, please visit www.ribolia.com.
About Mingxin Capital
Panlin Capital was founded in 2006 as an international private equity fund focused on investing in growth-stage high-tech enterprises. Panlin Capital is committed to pooling global resources to help Chinese biopharmaceutical companies expand into international markets and become world-leading enterprises.
About Kunshan Guoke Venture Capital Co., Ltd.
Kunshan High-Tech Venture Capital Co., Ltd. (Kunshan High-Tech VC) was established in 2012 as a state-owned venture capital platform wholly owned by Kunshan High-Tech Group Co., Ltd. With a registered capital of 300 million yuan, it adopts a dual-driven model of direct investment and fund investment. Focusing on equity investment and industrial incubation, the company emphasizes information technology, intelligent manufacturing, biomedicine, new energy, and new materials, continuously investing in "two new" enterprises. Kunshan High-Tech VC is one of the existing shareholders of the company.
About Kunshan Guoke Venture Capital
Kunshan Guoke Venture Capital Co., Ltd. (Kunshan Guoke Venture Capital) was established in 2001, with a registered capital of 725 million RMB. It is a venture capital company under Kunshan Venture Holding Co., Ltd. Its business scope includes venture capital investment and management of venture capital funds for high-tech enterprises and technology innovation companies. The investment fields cover electronics, metal materials, biomedicine, chip design, high-end equipment, rapid prototyping manufacturing, optoelectronic industry, and many others, laying a solid foundation for the development of relevant industries in Kunshan City. Kunshan Guoke Venture Capital is one of the existing shareholders of the company.
About Chouqin Venture Capital
Chouqin Venture Capital was founded in 2015, with investment areas covering healthcare, new-generation information technology, high-end manufacturing, and more. The companies it has invested in include Younuojin Biotech, Aijie Boya, Xipu Sunshine, and Anging Computer, among others. Chouqin Venture Capital also participated in the company's previous round of financing.
About Panlin Capital
Panlin Capital is a VC with both professionalism and influence in the two fields of healthcare and technology. Established in 2010, Panlin Capital adheres to the investment theme of "Technology creates the future, innovation leads upgrading," focusing on the healthcare and technology sectors, and seeks out angel to A-round projects. It is committed to "finding entrepreneurs among scientists and fostering innovators among entrepreneurs." In the healthcare sector, Panlin invests in innovative drug development companies that address unmet clinical needs for the prevention, diagnosis, and treatment of major diseases, as well as innovative medical device development companies, while exploring derivative investment opportunities in life sciences and biotechnology. In the technology sector, Panlin invests in To B enterprises (enterprise services and data intelligence equipment) that meet cost-reduction, efficiency-improvement, and quality-enhancement demands for B-end users, as well as in hard-tech companies (equipment and key components) that achieve independent control over core technologies. Prior to this round, Panlin Capital has led or participated in five rounds of financing for the company, making it the most frequent investor.
About Zhuhai Softbank Xinchuang
Zhuhai Softbank Xinchuang, as the fund manager of Shenzhen Xinchuang Medical Private Equity Investment Fund Partnership (Limited Partnership), is a Renminbi venture capital and private equity fund management company dedicated to investing in outstanding high-growth, high-tech enterprises in the Greater China region. The team originates from the healthcare investment team of Softbank China Capital (SBCVC) and has successfully invested in a series of excellent companies such as Di'an Diagnosis, BGI, Pulnovo Medical, and Edan Instruments. The main investment areas cover healthcare, including cell and gene therapy, AI and digital healthcare, synthetic biology, brain science, and more.
About Langma Feng Venture Capital
Langmafeng Venture Capital was founded in September 2007, with offices in Beijing, Shenzhen, and Shanghai. Its investment scope extends globally, primarily focusing on high-tech industries such as healthcare, semiconductors, artificial intelligence, advanced manufacturing, automotive transportation, and new energy. To date, it has invested in 128 companies, with 38 listed companies and more than ten either in the process of going public or under listing review. Over the past 18 years since its establishment, Langmafeng Venture Capital has consistently been committed to promoting the rapid development of innovative enterprises. Through precise investment insights and professional strategies, it has infused capital and resources into numerous innovative companies, helping them stand out in the market and achieve rapid growth. Meanwhile, Langmafeng Venture Capital issues venture capital funds, enabling investors to share in the growth dividends of high-tech enterprises, thereby earning the trust of investors and widespread acclaim in the business community.